Compare Goodyear Tire & Rubber Co (GT) vs Novartis AG (NVS) Price & Performance

Goodyear (GT) trades at $4.68, down 0.21% on the day, with a bearish technical signal and weak profitability metrics including a negative net income margin and ROE. Recent earnings show mixed results, with a Q2 2026 loss of $0.61 per share beating expectations but revenue declining. The company's restructuring efforts focus on premium tire segments and cost management, while cash flow trends show modest improvement with a net cash flow of $46 million in 2025.

The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests upside with a $8.00 price target. Key risks include volume pressure, competitive threats, and execution of the turnaround plan. Investment opportunity hinges on successful margin expansion and debt reduction, though near-term volatility is likely amid macroeconomic headwinds.

Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.

The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.